Article

Botulinum Toxin Type A: Efficacy in the management of Lower Limb Spasticity in Children with Genetic Disorders

2024-07-23

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Botulinum toxin type A (BoNT) is a well-established therapeutic modality for the treatment of lower limb spasticity in children with cerebral palsy. <bold>Objective:</bold> To assess the functional outcomes and tolerability of BoNT injection for the treatment of lower limb spasticity in children with neurometabolic/genetic disorders. <bold>Methods:</bold> We con...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b3a8ceaf-6876-5879-96a6-d8641c6ff821
DOI: 10.21203/rs.3.rs-4548232/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Botulinum Toxin Type A: Efficacy in the management of Lower Limb Spasticity in Children with Genetic DisordersDOI 10.21203/rs.3.rs-4548232/v1Read

Botulinum Toxin Type A: Efficacy and Safety Profile in the Treatment of Lower Limb Spasticity in Children with genetic DisordersSemantic proximity Read

Botulinum toxin as adjuvant therapy for hypertonic dysfunction in a neuro-rehabilitation cohortSemantic proximity Read

Update on the Genetics of Spastic ParaplegiasSemantic proximity Read

Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approachesSemantic proximity Read

Characteristics of individuals with cerebral palsy across the United StatesSemantic proximity Read

Physician Approaches to the Pharmacologic Treatment of Dystonia in Cerebral PalsySemantic proximity Read

Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology.Semantic proximity Read

Clinical and electrophysiologic features of the Pediatric hereditary neuropathy with liability to pressure palsiesSemantic proximity Read

Childhood dystonia.Semantic proximity Read

Rare Serious Etiologies in Patients Admitted to Pediatric Clinics with Acquired TorticollisSemantic proximity Read

Safety and Efficacy of Vesemnogene Lantuparvovec, an AAV-Based Gene Therapy in Young Children Under 24 Months with Spinal Muscular Atrophy in Low- and Middle-Income Countries. Second Interim Report (August 2025)Semantic proximity Read

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read